Eli Lilly becomes first drugmaker to hit $1 trillion market value on . . . Eli Lilly became the first drugmaker to reach a $1 trillion market valuation on Friday, driven by the rapid growth of its weight-loss drugs Mounjaro and Zepbound The milestone highlights Lilly’s emergence as a major player in the booming obesity treatment market
Zepbound maker Eli Lilly hits $1T market cap - New York Post Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse
Zepbound mania pushes Eli Lilly past $1 trillion- Fast Company Eli Lilly becomes first health-care company to hit $1 trillion Zepbound and Mounjaro posted triple-digit revenue growth, making Lilly the first health-care firm to reach a trillion-dollar valuation
Eli Lilly hits $1 trillion market value, first for health care company Mounjaro achieved “blockbuster” status – meaning it generated more than $1 billion in annual sales – during its first full year on the market Eli Lilly then won approval in late 2023 for tirzepatide as a treatment for obesity, which is sold as Zepbound and now competes with Novo Nordisk’s Wegovy